<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bone Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Bone Oncol</journal-id><journal-title-group><journal-title>Journal of Bone Oncology</journal-title></journal-title-group><issn pub-type="ppub">2212-1366</issn><issn pub-type="epub">2212-1374</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29963367</article-id><article-id pub-id-type="pmc">6024259</article-id><article-id pub-id-type="publisher-id">S2212-1374(17)30024-6</article-id><article-id pub-id-type="doi">10.1016/j.jbo.2018.04.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Ya</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Zewei</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Yanping</given-names></name><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Cao</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamar</surname><given-names>Santoshi</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Xiaoqian</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jifei</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jingqing</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Na</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Lei</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yihao</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Zuozhang</given-names></name><email>yangzuozhang@163.com</email><email>772488163@qq.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff0001"><label>a</label>Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, PR China</aff><aff id="aff0002"><label>b</label>The Kunming Medical University, Kunming, Yunnan 650000, PR China</aff><aff id="aff0003"><label>c</label>Department of Pharmacy, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, PR China</aff><aff id="aff0004"><label>d</label>Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, PR China</aff><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding authors. <email>yangzuozhang@163.com</email><email>772488163@qq.com</email></corresp><fn id="fn1"><label>1</label><p id="notep0000">These authors contributed equally to this work, and each is considered as a first author.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>5</month><year>2018</year></pub-date><volume>12</volume><fpage>54</fpage><lpage>60</lpage><history><date date-type="received"><day>7</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>4</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Authors</copyright-statement><copyright-year>2018</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0001"><sec><title>Study Design</title><p>Meta-analysis.</p></sec><sec><title>Background</title><p>Although some new insights have been offered for clinical and scientific relevance, minor progress has been made in osteosarcoma treatment after a dramatic survival improvement in the late 1980s with the addition of chemotherapy to surgery. Intensified chemotherapy strategies have been suggested to increase the survival rate of patients with osteosarcoma. We performed this study to access whether intensified chemotherapy strategiesincreased survival outcomes of osteosarcoma patients compared with conventional chemotherapy strategies.</p></sec><sec><title>Methods</title><p>MEDLINE/PubMed, EMBASE, BIOSIS Previews, and Cochrane Library were searched from database set up to October2016. Randomized controlled trials (RCTs) and comparative clinical trials (CCTs) on intensified versus conventional chemotherapy strategies for osteosarcoma patients met the inclusion criteria, and the methodological quality standard were retrieved and reviewed. Data on participant characteristics, interventions, follow-up period, and outcomes were extracted from the included studies and analyzed by Review Manager 5.3.</p></sec><sec><title>Results</title><p>12 studies (8 RCTs and 4CCT) involving 4112 patients were selected. There were no significant differences between intensified and conventional chemotherapy strategies group in 3-year event-free survival (OR, 1.01; 95% CI, [0.74&#x02013;1.37]; P&#x0202f;=&#x0202f;0.97), 5-year event-free survival (OR, 1.00; 95% CI, [0.86&#x02013;1.17]; P&#x0202f;=&#x0202f;0.97), and 5-year overall survival (OR, 1.04; 95% CI, [0.87&#x02013;1.26]; P&#x0202f;=&#x0202f;0.64), and good histologic response to preoperative chemotherapy (OR, 1.12; 95% CI, [0.78&#x02013;1.60]; P&#x0202f;=&#x0202f;0.55). Pooled analysis of local recurrence rate showed that local recurrence rate was significantly decreased in the intensified group compared with that in the conventional group (OR, 0.60; 95% CI, [0.42&#x02013;0.85]; P&#x0202f;=&#x0202f;0.004).</p></sec><sec><title>Conclusions</title><p>Intensified chemotherapy might not be a preferred treatment for all of the osteosarcoma patients.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Meta-analysis</kwd><kwd>High dosage</kwd><kwd>Chemotherapy</kwd><kwd>Osteosarcoma</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0007">Osteosarcoma is the most common bone malignancy (incidence:0.2&#x02013;0.3/100,000/year) with a predilection for adolescents and young adults <xref rid="bib0001" ref-type="bibr">[1]</xref>. Osteosarcoma was considered to be an incurable disease before 1970s with 5-year survival rate approximately10&#x02013;20%, indicating very poor prognosis <xref rid="bib0002" ref-type="bibr">[2]</xref>. After the introduction of adjuvant chemotherapy, the cumulative 5-year survival has improved to 60&#x02013;80%, indicating that adjuvant chemotherapy is vital for long-term survival of osteosarcoma.</p><p id="para0008">Currently, the combination of surgical removal of the tumor and systemic multidrug chemotherapy mainly consisting of methotrexate, adriamycin and cisplatin with or without ifosfamide, is the standard strategy to treat conventional osteosarcoma <xref rid="bib0003" ref-type="bibr">[3]</xref>. As a second-line chemotherapy strategy, combinations of gemcitabine with docetaxel seemed to show greater efficacy, with milder toxicity, when compared to pirarubicin-based chemotherapy for relapsed and refractory osteosarcoma <xref rid="bib0004" ref-type="bibr">[4]</xref>. Moreover, several investigators have demonstrated that caffeine, a DNA-repair inhibitor, improved 5-year event-free survival to 75%, when added to ADM- or CDDP-based chemotherapy in patients without metastasis at the initial examination <xref rid="bib0005" ref-type="bibr">[5]</xref>. Also, some promising novel agents, such as IGF-1R antibody or a mTOR inhibitor, are currently in Phase I/II clinical trials osteosarcoma <xref rid="bib0006" ref-type="bibr">[6]</xref>. IFN-&#x003b1; has been associated with activity against osteosarcomas in vitro, in animal models, and in patients with metastatic disease. Owing to its antiproliferative,differentiation-inducing,apoptotic,andantiangiogenicproperties,anditsclinicalactivityhasbeendemonstratedinseveralcancers <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>. Muramyltripeptide (MTP) phosphatidylethanolamine (MTP-PE) has been encapsulated in liposomes to deliver the agent selectively tomonocytes and macrophages to activate them to become tumoricidal, and the effect of MTP has been confirmed in rodentxenograftmodelsandinspontaneouscanine OS <xref rid="bib0010" ref-type="bibr">[10]</xref>. The addition of novel agents to the standard MAP chemotherapy may provide improvements in outcome for patients with osteosarcoma.</p><p id="para0009">Although some new insights have been offered for clinical and scientific relevance, minor progress has been made in osteosarcoma treatment after a dramatic survival improvement in the late 1980s with the addition of chemotherapy to surgery. Multiagent or intensified chemotherapy strategies have been suggested to improve the histological response of tumor cells, and finally increase the survival rate of patients with osteosarcoma as well as other malignancies <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>.</p><p id="para0010">Meanwhile, there are conflicting results reported when administrating more-intensive agents in the process of chemotherapy. Dose intensification will bring more therapy toxicity and expense for osteosarcoma patients. Moreover, many researchers thought that the inherent sensitivity of tumor cells to chemotherapeutic drugs can not be changed by increasing chemotherapy dose, thus the chemotherapy-induced necrosis rate levels may be not increased in theory. A recently reported study displayed that dose intensification with high-dose chemotherapy did not increase the probability of survival <xref rid="bib0013" ref-type="bibr">[13]</xref>.</p><p id="para0011">By summarizing the evidence from randomized controlled trials (RCTs) and comparative observational studies (CCTs), we performed this meta-analysis and aimed to gain a better understanding of whether the high drug dosage can improve the histological response of tumor cells, thus improving the patient's survival compared with conventional-dose chemotherapy.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Search for eligible studies</title><p id="para0012">We retrieved electronic databases of PubMed, Ovid, the Cochrane library, and CNKI using the following keywords: &#x02018;&#x02018;osteosarcoma&#x02019;&#x02019;, &#x0201c;chemotherapy&#x0201d;, &#x0201c;survival&#x0201d; (from database set up to October 2016 to identify the eligible articles. The reference lists of retrieved articles and relevant reviews were reviewed manually to find additional relevant studies.</p></sec><sec id="sec0004"><label>2.2</label><title>Inclusion and exclusion criteria</title><p id="para0013">Articles were selected if they met the following general criteria:</p><p id="para0014">(1) Randomized controlled trials (RCTs) or comparative observational studies (CCTs); (2) subjects were diagnosed with osteosarcoma; (3) More intensified chemotherapy strategies in the treatment group than the control group administered conventional chemotherapy strategies; (4) clear survival rate.</p><p id="para0015">Articles were excluded if there were: (1) Patients with metastases or history of cancer; (2) articles in non-English; (3) The study type of letters, case reports, editorials or reviews; (4) articles with incomplete raw data.</p></sec><sec id="sec0005"><label>2.3</label><title>Data extraction</title><p id="para0016">For included articles, two authors (&#x02026;and&#x02026;) independently extracted and collected data from full-text articles. If there was disagreement, another author (&#x02026;) joined to reach an agreement. The following information of each included article was collected: first author, year of publication, country, research design, sample size, duration of chemotherapy, planned number of courses, cycles, and dosage of each drug in the chemotherapy period, overall duration of chemotherapy and the evaluated outcomes.</p></sec><sec id="sec0006"><label>2.4</label><title>Study quality</title><p id="para0017">Two independent authors (&#x02026; and &#x02026;) assessed the methodological quality of the included studies based on the physiotherapy evidence database (PEDro) scale <xref rid="bib0014" ref-type="bibr">[14]</xref>. This scale consists of a list of 11 criteria, covering aspects of randomization method, allocation concealment, blinding referring to the study subjects, investigators and outcome assessors, attrition bias and baseline conditions. The first criterion did not score, and the other criterion conferred 1 point to the total score of 10 points. Studies with PEDro score&#x0202f;&#x02265;&#x0202f;6 were considered as being high quality.</p></sec><sec id="sec0007"><label>2.5</label><title>Statistical analysis</title><p id="para0018">Cochrane systematic review software RevMan 5.3 was used in this meta-analysis. &#x003c7;2 test was used to analysis heterogeneity among studies. The fixed effects model or random-effects model was used for the pooled analysis of data from trials without or with heterogeneity (<italic>I<sup>2</sup><sup>&#x0202f;</sup></italic>&#x0003e;&#x0202f;50%). Sensitivity analysis was performed to find the source of heterogeneity. Primary outcomes were 3-year event-free survival, 5-year event-free survival, and 5-year overall survival. Secondary outcomes were histological response to preoperative chemotherapy (the percentage of tumor necrosis), local recurrence rate, and toxicity.</p></sec></sec><sec id="sec0008"><label>3</label><title>Results</title><sec id="sec0009"><label>3.1</label><title>Search result and characteristic of included studies</title><p id="para0019">A total of 964 relevant titles were identified through database searching. Of these, 918 were excluded after reviewing abstracts or titles for an unrelated topic; not intensified chemotherapy; not osteosarcoma; or non-English writing. Finally, 46articles were retrieved after full-text reviewing, and 12 studies met the inclusion criteria (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). The obtained 12 studies were all comparative studies between intensified and conventional chemotherapy strategies. The characteristics of the 12 included studies were listed in <xref rid="tbl0001" ref-type="table">Table 1</xref>
<xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, of which 8 studies were RCT and 4 studies were CCT. A total of 4112 patients were involved in this meta-analysis. In two studies, the administered chemotherapy scheme was identical for the treatment and control groups except that a higher dose was used in the treatment group. In seven study, chemotherapy combinations were added for the treatment group. In another three studies, the chemotherapy treatment was extended with the same chemotherapy combinations, equivalent to an increase in the cumulative dose. For the study of Meyers PA 2005, 2&#x0202f;&#x000d7;&#x0202f;2 factorial design was performed to evaluate the effect of addition of Ifosfamide and/or MuramylTripeptide to standard chemotherapy.<fig id="fig0001"><label>Fig. 1</label><caption><p>The flow chart of screening included studies.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap id="tbl0001" position="float"><label>Table 1</label><caption><p>The characteristics of the 12 included studies.</p></caption><alt-text id="alt0007">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">References</th><th valign="top">Study location</th><th valign="top">Type of study</th><th valign="top">Duration (weeks)</th><th valign="top">No. of Patients Included</th><th valign="top">Age (years)</th><th valign="top">Timing of Surgery (weeks)</th><th valign="top">Outcome measure</th><th valign="top">Follow-up time (years)</th></tr></thead><tbody><tr><td valign="top">Bacci G 1986</td><td valign="top">Italy</td><td valign="top">RCT</td><td valign="top">7:7</td><td valign="top">106</td><td valign="top">&#x0003c;50</td><td valign="top">NA</td><td valign="top">5-year disease free survival rate, histological response rate,5-year overall survival rate, percentage of limb salvage rate, toxicity of therapy</td><td valign="top">2.5&#x02013;5.5</td></tr><tr><td valign="top">Souhami RL 1997</td><td valign="top">UK</td><td valign="top">RCT</td><td valign="top">44:18</td><td valign="top">391</td><td valign="top">&#x02264;40</td><td valign="top">7:9</td><td valign="top">5-year disease free survival rate, local recurrence rate, histological response rate, 5-year overall survival rate, percentage of limb salvage rate, toxicity of therapy</td><td valign="top">5&#x02013;6</td></tr><tr><td valign="top">Meyers PA 1998</td><td valign="top">USA</td><td valign="top">RCT</td><td valign="top">NA</td><td valign="top">73</td><td valign="top">&#x02264;36.4</td><td valign="top">11:7</td><td valign="top">5-year disease free survival rate, local recurrence rate, histological response</td><td valign="top">3.5&#x02013;9</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Bacci G 2003</td><td valign="top">Italy</td><td valign="top">CCT</td><td valign="top">NA</td><td valign="top">367</td><td valign="top">&#x0003c;50</td><td valign="top">13:11</td><td valign="top">5-year disease free survival rate, local recurrence rate, toxicity of therapy</td><td valign="top">7.5&#x02013;10</td></tr><tr><td valign="top">Lewis IJ 2007</td><td valign="top">UK</td><td valign="top">RCT</td><td valign="top">15:21</td><td valign="top">497</td><td valign="top">&#x0003c;40</td><td valign="top">6:6</td><td valign="top">5 year disease free survival rate;5 year overall survival rate; local recurrence rate, toxicity of therapy</td><td valign="top">9&#x02013;10.5</td></tr><tr><td valign="top">Ferrari S 2012</td><td valign="top">Italy</td><td valign="top">RCT</td><td valign="top">34:44</td><td valign="top">246</td><td valign="top">&#x02264;40</td><td valign="top">11: 8</td><td valign="top">5-year disease free survival rate, 5 year overall survival, toxicity of therapy</td><td valign="top">6.3</td></tr><tr><td valign="top">Choeyprasert W 2014</td><td valign="top">Thailand</td><td valign="top">CCT</td><td valign="top">36:31</td><td valign="top">66</td><td valign="top">&#x02264;18</td><td valign="top">NA</td><td valign="top">histological response rate, 3-year disease free survival rate, 3-year overall survival rate, local recurrence rate</td><td valign="top">2.47</td></tr><tr><td valign="top">Meyers PA 2005</td><td valign="top">USA</td><td valign="top">RCT</td><td valign="top">31&#x02013;38</td><td valign="top">677</td><td valign="top">&#x0003c;30</td><td valign="top">10</td><td valign="top">5-year disease free survival rate, 3-year disease free survival rate, toxicity of therapy</td><td valign="top">4.8</td></tr><tr><td valign="top">Schwartz CL 2016</td><td valign="top">Texas</td><td valign="top">CCT</td><td valign="top">36:28</td><td valign="top">242</td><td valign="top">&#x0003c;31</td><td valign="top">11</td><td valign="top">histological response rate, 3-year overall survival rate, toxicity of therapy</td><td valign="top">4.75</td></tr><tr><td valign="top">Bielack SS 2015</td><td valign="top">UK</td><td valign="top">RCT</td><td valign="top">29:67</td><td valign="top">716</td><td valign="top">&#x02264;40</td><td valign="top">11</td><td valign="top">Local recurrence, 5-year disease free survival rate, 5-year overall survival rate, 3-year disease free survival rate, 3-year overall survival rate, toxicity of therapy</td><td valign="top">3.67</td></tr><tr><td valign="top">Marina NM 2016</td><td valign="top">USA</td><td valign="top">RCT</td><td valign="top">40:29</td><td valign="top">618</td><td valign="top">&#x02264;40</td><td valign="top">NA</td><td valign="top">3-year disease free survival rate, 3-year overall survival rate, toxicity of therapy</td><td valign="top">5.17</td></tr><tr><td valign="top">Iwamoto Y 2009</td><td valign="top">Japan</td><td valign="top">CCT</td><td valign="top">NA</td><td valign="top">113</td><td valign="top">&#x02264;30</td><td valign="top">11</td><td valign="top">histological response rate, 5-year disease free survival rate, 5-year overall survival rate, toxicity of therapy</td><td valign="top">6.3</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0010"><label>3.2</label><title>Assessing study quality</title><p id="para0020">12 eligible studies were incorporated for study quality assessment. The total scores for all included studies assessed by PEDro quality criteria ranged from 5 to 8 (<xref rid="tbl0002" ref-type="table">Table 2</xref>). Eleven studies were conferred with high quality (PEDro score&#x0202f;&#x02265;&#x0202f;6), and one study was of low quality (PEDro score&#x0202f;&#x0003c;&#x0202f;6). The two independent reviewers reached consensuses on the scoring of all items without any disagreement. Nevertheless, the overall methodological quality was generally fair.<table-wrap id="tbl0002" position="float"><label>Table 2</label><caption><p>The total scores for all included studies assessed by PEDro quality criteria.</p></caption><alt-text id="alt0008">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Included studies</th><th colspan="11" align="left" valign="top">Item PEDro score<hr/></th><th valign="top">Total score</th></tr><tr><th valign="top"/><th valign="top">1</th><th valign="top">2</th><th valign="top">3</th><th valign="top">4</th><th valign="top">5</th><th valign="top">6</th><th valign="top">7</th><th valign="top">8</th><th valign="top">9</th><th valign="top">10</th><th valign="top">11</th><th valign="top"/></tr></thead><tbody><tr><td valign="top">Bacci G 1986</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top">Souhami RL 1997</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top">Meyers PA 1998</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">7</td></tr><tr><td valign="top">Bacci G 2003</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">5</td></tr><tr><td valign="top">Lewis IJ 2007</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top">Ferrari S 2012</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">7</td></tr><tr><td valign="top">Choeyprasert W 2014</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top">Meyers PA 2005</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">7</td></tr><tr><td valign="top">Schwartz CL 2016</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top">Bielack SS 2015</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">8</td></tr><tr><td valign="top">Marina NM 2016</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">8</td></tr><tr><td valign="top">Iwamoto Y 2009</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">&#x02212;</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">6</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr></tbody></table></table-wrap></p></sec><sec id="sec0011"><label>3.3</label><title>3-year event-free survival</title><p id="para0021">For 3 included studies, the data of 3-year event-free survival rates was reported. The 3-year event-free survival rate was 66.4% in the intensified group and 67.2% in the conventional group. Pooled analysis of 3-year event-free survival rate showed that there was no difference between the two groups (OR, 1.01; 95% CI, [0.74&#x02013;1.37]; P&#x0202f;=&#x0202f;0.97). As there was heterogeneity between the study estimates (I<sup>2</sup><sup>&#x0202f;</sup>=&#x0202f;64%), the random-effect model was used (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>).<fig id="fig0002"><label>Fig. 2</label><caption><p>Pooled analysis of 3-year event-free survival rate between intensified and conventional chemotherapy strategies.</p></caption><alt-text id="alt0002">Fig 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec0012"><label>3.4</label><title>5-year event-free survival</title><p id="para0022">For 8 included studies, the data of 5-year event-free survival rates was reported. The 5-year event-free survival rate was 53.7% in the intensified group and 53.4% in the conventional group. Pooled analysis of 5-year event-free survival rate showed that there was no difference between the two groups (OR, 1.00; 95% CI, [0.86&#x02013;1.17]; P&#x0202f;=&#x0202f;0.97). As there was no evidence of heterogeneity between the study estimates (I<sup>2</sup><sup>&#x0202f;</sup>=&#x0202f;49%), the fixed-effect model was used (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>).<fig id="fig0003"><label>Fig. 3</label><caption><p>Pooled analysis of 5-year event-free survival rate between intensified and conventional chemotherapy strategies.</p></caption><alt-text id="alt0003">Fig 3</alt-text><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec0013"><label>3.5</label><title>5-year overall survival</title><p id="para0023">For 7 studies, the data of 5-year overall survival rates was reported. The 5-year overall survival rates was 63.1% in the intensified group, and 61.9% in the conventional group. Pooled analysis of 5-year overall survival rates showed that there was no statistically significant difference between the two chemotherapy treatments (OR, 1.04; 95% CI, [0.87&#x02013;1.26]; P&#x0202f;=&#x0202f;0.64). As there was no evidence of heterogeneity between the study estimates (I<sup>2</sup><sup>&#x0202f;</sup>=&#x0202f;10%), the fixed-effect model was used (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>).<fig id="fig0004"><label>Fig. 4</label><caption><p>Pooled analysis of 5-year overall survival rates between intensified and conventional chemotherapy strategies.</p></caption><alt-text id="alt0004">Fig 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec0014"><label>3.6</label><title>Local recurrence rate</title><p id="para0024">For 6 studies, the data of local recurrence rate was reported with a follow-up of 5 years. The local recurrence rate was 6.25% in the intensified group and 10.4% in the conventional group. Pooled analysis of local recurrence rate showed that local recurrence rate was significantly decreased in the intensified group compared with that in the conventional group (OR, 0.60; 95% CI, [0.42&#x02013;0.85]; P&#x0202f;=&#x0202f;0.004). As there was no evidence of heterogeneity between the study estimates (I<sup>2</sup><sup>&#x0202f;</sup>=&#x0202f;38%), the fixed-effect model was used (<xref rid="fig0005" ref-type="fig">Fig. 5</xref>).<fig id="fig0005"><label>Fig. 5</label><caption><p>Pooled analysis of local recurrence rate between intensified and conventional chemotherapy strategies.</p></caption><alt-text id="alt0005">Fig 5</alt-text><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec0015"><label>3.7</label><title>The effect of histologic response to preoperative chemotherapy on survival</title><p id="para0025">For 8 studies, the data of rate of good histologic response to preoperative chemotherapy (90% tumor necrosis and above) was reported. The rate of good histologic response was 45.5% in the intensified group, and 41.0% in the conventional dose group. Pooled analysis of good histologic response showed that there was no statistically significant difference between the two chemotherapy treatments (OR, 1.12; 95% CI, [0.78&#x02013;1.60]; P&#x0202f;=&#x0202f;0.55), suggesting that the intensified chemotherapy strategies did not increase good histological response rate of tumor to the chemotherapy which was highly correlated with longer survival. As there was heterogeneity between the study estimates (I<sup>2</sup><sup>&#x0202f;</sup>=&#x0202f;64%), the random-effect model was used (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>).<fig id="fig0006"><label>Fig. 6</label><caption><p>Pooled analysis of the rate of good histologic response to preoperative chemotherapy between intensified and conventional chemotherapy strategies.</p></caption><alt-text id="alt0006">Fig 6</alt-text><graphic xlink:href="gr6"/></fig></p></sec><sec id="sec0016"><label>3.8</label><title>Toxicity</title><p id="para0026">The data of toxicity of therapy was reported in 10 studies, while the detail was not available in two studies. We displayed the occurrence rate of Grade 3 or greater toxicity during protocol chemotherapy in the intensified and conventional group in <xref rid="tbl0003" ref-type="table">Table 3</xref>. Among those studies, two studies <xref rid="bib0027" ref-type="bibr">[27]</xref>, <xref rid="bib0028" ref-type="bibr">[28]</xref> performed statistical analysis, and showed that there was an significant increase in the occurrence of leucopenia, thrombocytopenia, RBC transfusion, PLT transfusion, neutropenic fever, and neutropeniain the intensified group compared with that of conventional group (P&#x0003c;0.001).<table-wrap id="tbl0003" position="float"><label>Table 3</label><caption><p>Grade 3 or greater toxicity during protocol chemotherapy.</p></caption><alt-text id="alt0009">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Toxicity of therapy</th><th valign="top">Bacci G 1986</th><th valign="top">Souhami RL 1997</th><th valign="top">Bacci G 2003</th><th valign="top">Lewis IJ 2007</th><th valign="top">Ferrari S 2012</th><th valign="top">Meyers PA 2005</th><th valign="top">Bielack SS 2015</th><th valign="top">Marina NM 2016</th></tr></thead><tbody><tr><td valign="top">Hearing loss</td><td valign="top"/><td valign="top">2%:0%</td><td valign="top"/><td valign="top">3%:0%</td><td valign="top"/><td valign="top">11%</td><td valign="top"/><td valign="top">1%:3%</td></tr><tr><td valign="top">Leucopenia</td><td valign="top"/><td valign="top">73%:75%</td><td valign="top"/><td valign="top"/><td valign="top">95%:64%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top">7%:4%</td></tr><tr><td valign="top">Thrombocytopenia</td><td valign="top"/><td valign="top">28%:46%</td><td valign="top">21%:7%</td><td valign="top"/><td valign="top">84%:49%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top">83%:78%</td></tr><tr><td valign="top">Nausea and vomiting</td><td valign="top"/><td valign="top">66%:74%</td><td valign="top"/><td valign="top">53%:48%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Mucositis</td><td valign="top"/><td valign="top">14%:20%</td><td valign="top"/><td valign="top">35%:27%</td><td valign="top"/><td valign="top">30%:33%</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Alopecia</td><td valign="top"/><td valign="top">90%:86%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Renal impairment</td><td valign="top"/><td valign="top">3%:2%</td><td valign="top"/><td valign="top"/><td valign="top">3.4%:2.4%</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Liver</td><td valign="top"/><td valign="top">12%:1%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Infection</td><td valign="top"/><td valign="top">18%:21%</td><td valign="top"/><td valign="top">25%:27%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">53%:36%</td></tr><tr><td valign="top">Skin effects</td><td valign="top"/><td valign="top">2%:1%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Neurotoxicity</td><td valign="top"/><td valign="top">1%:1%</td><td valign="top">3%:0%</td><td valign="top">1%:0%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Pulmonary</td><td valign="top"/><td valign="top">1%:0%</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Delayed excretion</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">8.2%:7.6%</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">RBC transfusion</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">78%:35%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">PLT transfusion</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">77%:58%(P&#x0003c;0.001)</td><td valign="top">64%:25%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Neutropenic fever</td><td valign="top"/><td valign="top"/><td valign="top">14%:2%</td><td valign="top"/><td valign="top">71%:42%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top">73%:50%</td></tr><tr><td valign="top">Neutropenia</td><td valign="top"/><td valign="top"/><td valign="top">48%:15%</td><td valign="top">76%:92%(P&#x0003c;0.001)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">90%:89%</td></tr><tr><td valign="top">Cardiotoxicity</td><td valign="top">11%</td><td valign="top">2%:0%</td><td valign="top">0.5%:1.2%</td><td valign="top">1%:3%</td><td valign="top">3.4%:5.6%</td><td valign="top"/><td valign="top">4%:4%</td><td valign="top">1.3%:1%</td></tr><tr><td valign="top">Any toxicities</td><td valign="top">&#x025a1;</td><td valign="top">&#x025a1;</td><td valign="top">&#x025a1;</td><td valign="top">96%:97%</td><td valign="top">&#x025a1;</td><td valign="top">&#x025a1;</td><td valign="top">&#x025a1;</td><td valign="top">94%:95%</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec0017"><label>4</label><title>Discussion</title><p id="para0027">Neoadjuvant chemotherapy, as a major therapeutic modality, is essential for long-term survival in the treatment of osteosarcoma <xref rid="bib0029" ref-type="bibr">[29]</xref>. However, optimal chemotherapy protocol regarding the best chemotherapy regimen and the optimal intensity, remains unclear. Amounts of studies have shown that administrated dose of chemotherapy agents is closely related to the survival of patients with osteosarcoma <xref rid="bib0030" ref-type="bibr">[30]</xref>, <xref rid="bib0031" ref-type="bibr">[31]</xref>. To find the correlation between the chemotherapy intensity and patient survival, we performed this meta-analysis to access the intensified chemotherapy strategies on survival outcomes of osteosarcoma patients compared with conventional chemotherapy strategies. In this meta-analysis, we identified12 clinnical trails involving 4112 patient sex periencing chemotherapy for osteosarcoma. No significant differences were observed between intensified and conventional chemotherapy group in good histologic response rate to preoperative chemotherapy, 3-year event-free survival, 5-year event-free survival, and 5-year overall survival. While local recurrence rate was significantly decreased in the intensified group compared with that in the conventional chemotherapy group.</p><p id="para0028">The influence of chemotherapy dose and dose intensity on survival of patients with malignant disease has been studied in various settings <xref rid="bib0032" ref-type="bibr">[32]</xref>, <xref rid="bib0033" ref-type="bibr">[33]</xref>, <xref rid="bib0034" ref-type="bibr">[34]</xref>. Early in vitro and in vivo experiments both revealed that increases in dose intensity consistently associated with higher response rates, as well as more potential for cure <xref rid="bib0035" ref-type="bibr">[35]</xref>. A meta-analysis also showed that increased dose intensity is correlated with superior remission rates in advanced-stage intermediate-grade lymphoma <xref rid="bib0036" ref-type="bibr">[36]</xref>. However, recently some clinical trials of increased drug doses have shown inconsistent results, generally providing no prolong in survival while considerably increasing toxicity <xref rid="bib0037" ref-type="bibr">[37]</xref>, <xref rid="bib0038" ref-type="bibr">[38]</xref>, emphasizing that intensified chemotherapy may not be as important as previously considered.</p><p id="para0029">Histologic response rate to preoperative chemotherapy was an independent prognostic factor in osteosarcoma. Previous researches reported that patients with good histologic response would have higher survival rate <xref rid="bib0039" ref-type="bibr">[39]</xref>. In two of our included studies <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, intensified preoperative chemotherapy resulted in modest increases in favorable histologic response rate, no improvement in5 year disease-free or overall survival was observed. However, pooled analysis of all included studies did not display any difference in good histologic response rate to preoperative chemotherapy. A possible explanation for this result is that chemotherapy response may be mainly dependent on intrinsic tumor biology and not the intensity of chemotherapeutic agents.</p><p id="para0030">Local recurrence, an indicator of poor survival, was significantly decreased in dose-intensive group compared with that in dose control group, while this did not translate into a demonstrable survival benefit in this meta-analysis. This may be explained by that intensified chemotherapy would cause greater tumor cell kill, and the amount of tumor cell remains a low level in short term, so the local recurrence was lower, however, the long-term survival was not affected for the unchanged malignancy of the tumor.</p><p id="para0031">Importantly, the chemotherapy treatment of OS is associated with short and long term collateraltoxic effects <xref rid="bib0040" ref-type="bibr">[40]</xref>. Acutetoxicitiessuchasalopecia, myelosuppression, mucositis, and nausea and vomiting are common complications of most cytotoxic chemotherapy regimens <xref rid="bib0041" ref-type="bibr">[41]</xref>. The major causes of rare cases of toxic deaths have been early or late cardiac failure due to doxorubicin toxicity and sepsis following febrile neutropenia. Among those studies we extracted, there was an significant increase in the occurrence of leucopenia, thrombocytopenia, RBC transfusion, PLT transfusion, neutropenic fever, and neutropenia in the intensified group compared with that of conventional group. Combinations of gemcitabine with docetaxel seemed to show greater efficacy, with milder toxicity, when compared to pirarubicin-based chemotherapy for relapsed and refractory osteosarcoma <xref rid="bib0004" ref-type="bibr">[4]</xref>.</p><p id="para0032">There were some limitations in this meta-analysis. There is considerable heterogeneity among different studies. Firstly, osteosarcoma is consisted of various histopathologic subtypes. The administrated chemotherapy agents or schemes differed, influence of drug dosage and intensity on outcomes for patients might display intrinsic differences for different drugs. Further RCTs with high quality were needed to provide more reliable evidence. Despite these limitations, this meta-analysis can still provide some value for clinical practice.</p><p id="para0033">In conclusion, although the intensified chemotherapy decreased the local recurrence rate, long-term prognosis was similar between intensified and conventional chemotherapy in patients with osteosarcoma. Considered the higher cost or toxicity, there is no need to perform the intensified chemotherapy. Given that the survival rate of osteosarcoma could not be increased by intensified chemotherapy, it is expected to develop new therapeutic drugs for osteosarcoma in the future clinical investigation. Another direction the clinical investigation is heading for is to optimize the use of the active drugs, facilitating a possible personalized chemotherapy approach.</p></sec><sec id="sec0018"><title>Conflict of interest</title><p id="para0034">The authors declared that there is no conflict of interests in this work.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>G</given-names></name><name><surname>van</surname><given-names>JM</given-names></name><name><surname>Casali</surname><given-names>PG</given-names></name><name><surname>Siesling</surname><given-names>S</given-names></name><name><surname>Dei Tos</surname><given-names>AP</given-names></name></person-group><article-title>Rare cancers are not so rare: the rare cancer burden in Europe</article-title><source>Eur. J. Cancer</source><volume>47</volume><year>2011</year><fpage>2493</fpage><lpage>2511</lpage><pub-id pub-id-type="pmid">22033323</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>MA</given-names></name><name><surname>Carter</surname><given-names>SK</given-names></name></person-group><article-title>The therapy of osteogenic sarcoma: current status and thoughts for the future</article-title><source>J. Surg. Oncol.</source><volume>4</volume><year>1972</year><fpage>482</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">4566220</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Eilber</surname><given-names>F</given-names></name><name><surname>Giuliano</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Moseley</surname><given-names>S</given-names></name></person-group><article-title>Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial</article-title><source>J. Clin. Oncol.</source><volume>5</volume><year>1987</year><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">3543236</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>He</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name></person-group><article-title>Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience</article-title><source>Int. J. Clin. Oncol.</source><volume>18</volume><year>2013</year><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">22534798</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>H</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Asada</surname><given-names>N</given-names></name><name><surname>Morinaga</surname><given-names>T</given-names></name></person-group><article-title>Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma</article-title><source>Anticancer Res</source><volume>18</volume><year>1998</year><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">9584049</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>O'Day</surname><given-names>K</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name></person-group><article-title>Novel therapeutic agents for osteosarcoma</article-title><source>Expert Rev. Anticancer Ther.</source><volume>9</volume><year>2009</year><fpage>511</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">19374604</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>D</given-names></name><name><surname>Perisoglou</surname><given-names>M</given-names></name><name><surname>Bielack</surname><given-names>S</given-names></name><name><surname>Marina</surname><given-names>N</given-names></name></person-group><article-title>The role of interferons in the treatment of osteosarcoma</article-title><source>Pediatr. Blood Cancer</source><volume>54</volume><year>2010</year><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">19902521</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name><name><surname>Tarhini</surname><given-names>AA</given-names></name><name><surname>Zarour</surname><given-names>H</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name></person-group><article-title>Immunotherapy of cancer in 2012</article-title><source>CA Cancer J. Clin.</source><volume>62</volume><year>2012</year><fpage>309</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">22576456</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Tarhini</surname><given-names>AA</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?</article-title><source>J. Clin. Oncol.</source><volume>30</volume><year>2012</year><fpage>3773</fpage><lpage>3776</lpage><pub-id pub-id-type="pmid">23008298</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Chou</surname><given-names>AJ</given-names></name></person-group><article-title>Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma</article-title><source>Adv. Exp. Med. Biol.</source><volume>804</volume><year>2014</year><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">24924182</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Klasa</surname><given-names>RJ</given-names></name><name><surname>Murray</surname><given-names>N</given-names></name><name><surname>Coldman</surname><given-names>AJ</given-names></name></person-group><article-title>Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung</article-title><source>J. Clin. Oncol.</source><volume>9</volume><year>1991</year><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">1847968</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Longhi</surname><given-names>A</given-names></name><name><surname>Forni</surname><given-names>C</given-names></name><name><surname>Giacomini</surname><given-names>S</given-names></name></person-group><article-title>Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy</article-title><source>Oncol. Rep.</source><volume>8</volume><year>2001</year><fpage>883</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">11410803</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Boye</surname><given-names>K</given-names></name><name><surname>Del Prever</surname><given-names>AB</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Saeter</surname><given-names>G</given-names></name><name><surname>Tienghi</surname><given-names>A</given-names></name></person-group><article-title>High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study</article-title><source>Pediatr. Blood Cancer</source><volume>61</volume><year>2014</year><fpage>840</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">24254749</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Verhagen</surname><given-names>AP</given-names></name><name><surname>de Vet</surname><given-names>HC</given-names></name><name><surname>de Bie</surname><given-names>RA</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Boers</surname><given-names>M</given-names></name></person-group><article-title>The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus</article-title><source>J. Clinical Epidemiol.</source><volume>51</volume><year>1998</year><fpage>1235</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">10086815</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Gherlinzoni</surname><given-names>F</given-names></name><name><surname>Picci</surname><given-names>P</given-names></name><name><surname>Van Horn JR</surname><given-names>JaffeN</given-names></name></person-group><article-title>Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study</article-title><source>Eur. J. Cancer Clin. Oncol.</source><volume>22</volume><year>1986</year><fpage>1337</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">3493903</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>IJ</given-names></name><name><surname>Nooij</surname><given-names>MA</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><name><surname>Sydes</surname><given-names>MR</given-names></name><name><surname>Grimer</surname><given-names>R</given-names></name></person-group><article-title>Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup</article-title><source>J. Natl. Cancer Inst.</source><volume>99</volume><year>2007</year><fpage>112</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">17227995</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Casper</surname><given-names>E</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name></person-group><article-title>Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol</article-title><source>J. Clin. Oncol.</source><volume>16</volume><year>1998</year><fpage>2452</fpage><lpage>2458</lpage><pub-id pub-id-type="pmid">9667263</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Forni</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Longhi</surname><given-names>A</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name></person-group><article-title>Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome</article-title><source>J. Pediatr. Hematol. Oncol.</source><volume>25</volume><year>2003</year><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">14608193</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Souhami</surname><given-names>RL</given-names></name><name><surname>Craft</surname><given-names>AW</given-names></name><name><surname>Van der Eijken</surname><given-names>JW</given-names></name><name><surname>Nooij</surname><given-names>M</given-names></name><name><surname>Spooner</surname><given-names>D</given-names></name></person-group><article-title>Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup</article-title><source>Lancet</source><volume>350</volume><year>1997</year><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">9314869</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Ruggieri</surname><given-names>P</given-names></name><name><surname>Cefalo</surname><given-names>G</given-names></name><name><surname>Tamburini</surname><given-names>A</given-names></name><name><surname>Capanna</surname><given-names>R</given-names></name></person-group><article-title>Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1</article-title><source>J. Clin. Oncol.</source><volume>30</volume><year>2012</year><fpage>2112</fpage><lpage>2118</lpage><pub-id pub-id-type="pmid">22564997</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Choeyprasert</surname><given-names>W</given-names></name><name><surname>Pakakasama</surname><given-names>S</given-names></name><name><surname>Sirachainan</surname><given-names>N</given-names></name><name><surname>Songdej</surname><given-names>D</given-names></name><name><surname>Chuansumrit</surname><given-names>A</given-names></name></person-group><article-title>Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience</article-title><source>Asian Pacific J. Cancer Prevent.</source><volume>15</volume><year>2014</year><fpage>9823</fpage><lpage>9829</lpage></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Schwartz</surname><given-names>CL</given-names></name><name><surname>Krailo</surname><given-names>M</given-names></name><name><surname>Kleinerman</surname><given-names>ES</given-names></name><name><surname>Betcher</surname><given-names>D</given-names></name></person-group><article-title>Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate</article-title><source>J. Clin. Oncol. Offic. J. Am. Soc. Clin. Oncol.</source><volume>23</volume><year>2005</year><fpage>2004</fpage><lpage>2011</lpage></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Marina</surname><given-names>NM</given-names></name><name><surname>Smeland</surname><given-names>S</given-names></name><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Jovic</surname><given-names>G</given-names></name></person-group><article-title>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial</article-title><source>Lancet Oncol.</source><volume>17</volume><year>2016</year><fpage>1396</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">27569442</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Isu</surname><given-names>K</given-names></name><name><surname>Kawai</surname><given-names>A</given-names></name><name><surname>Tatezaki</surname><given-names>S</given-names></name></person-group><article-title>Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93&#x0202f;J and NECO-95&#x0202f;J</article-title><source>J Orthop Sci</source><volume>14</volume><year>2009</year><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">19662473</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>CL</given-names></name><name><surname>Wexler</surname><given-names>LH</given-names></name><name><surname>Krailo</surname><given-names>MD</given-names></name><name><surname>Teot</surname><given-names>LA</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name></person-group><article-title>Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the children's oncology group</article-title><source>Pediatr. Blood Cancer</source><volume>63</volume><year>2016</year><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">26398490</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Smeland</surname><given-names>S</given-names></name><name><surname>Whelan</surname><given-names>JS</given-names></name><name><surname>Marina</surname><given-names>N</given-names></name><name><surname>Jovic</surname><given-names>G</given-names></name></person-group><article-title>Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial</article-title><source>J Clin Oncol</source><volume>33</volume><year>2015</year><fpage>2279</fpage><lpage>2287</lpage><pub-id pub-id-type="pmid">26033801</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Ruggieri</surname><given-names>P</given-names></name><name><surname>Cefalo</surname><given-names>G</given-names></name><name><surname>Tamburini</surname><given-names>A</given-names></name><name><surname>Capanna</surname><given-names>R</given-names></name></person-group><article-title>Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1</article-title><source>J. Clinical Oncol.</source><volume>30</volume><year>2012</year><fpage>2112</fpage><lpage>2118</lpage><pub-id pub-id-type="pmid">22564997</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>IJ</given-names></name><name><surname>Nooij</surname><given-names>MA</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><name><surname>Sydes</surname><given-names>MR</given-names></name><name><surname>Grimer</surname><given-names>R</given-names></name></person-group><article-title>Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the european osteosarcoma intergroup</article-title><source>Cancerspectrum Knowl. Environ.</source><volume>99</volume><year>2007</year><fpage>112</fpage><lpage>128</lpage></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name><surname>Mirabello</surname><given-names>L</given-names></name><name><surname>Troisi</surname><given-names>RJ</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name></person-group><article-title>Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program</article-title><source>Cancer</source><volume>115</volume><year>2009</year><fpage>1531</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">19197972</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Beron</surname><given-names>G</given-names></name><name><surname>Winkler</surname><given-names>K</given-names></name></person-group><article-title>Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature</article-title><source>Cancer</source><volume>80</volume><year>1997</year><fpage>516</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">9241087</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Picci</surname><given-names>P</given-names></name></person-group><article-title>Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs</article-title><source>J Chemother</source><volume>8</volume><year>1996</year><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">8981189</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>WC</given-names></name><name><surname>Budman</surname><given-names>DR</given-names></name><name><surname>Korzun</surname><given-names>AH</given-names></name></person-group><article-title>Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma</article-title><source>N. Engl. J. Med.</source><volume>330</volume><year>1994</year><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="pmid">8080512</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>N</given-names></name></person-group><article-title>Importance of dose and dose intensity in the treatment of small-cell lung cancer</article-title><source>Cancer Chemother. Pharmacol.</source><volume>40</volume><issue>Suppl</issue><year>1997</year><fpage>S58</fpage><lpage>S63</lpage><pub-id pub-id-type="pmid">9272136</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name><surname>Foote</surname><given-names>M.</given-names></name></person-group><article-title>The importance of planned dose of chemotherapy on time: do we need to change our clinical practice?</article-title><source>Oncologist</source><volume>3</volume><year>1998</year><fpage>365</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">10388127</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Skipper</surname><given-names>HE</given-names></name></person-group><article-title>Kinetics of mammary tumor cell growth and implications for therapy</article-title><source>Cancer</source><volume>28</volume><year>1971</year><fpage>1479</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">5127796</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>RM</given-names></name><name><surname>Hryniuk</surname><given-names>WM</given-names></name><name><surname>Goodyear</surname><given-names>MD</given-names></name></person-group><article-title>The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma</article-title><source>J Clin Oncol</source><volume>9</volume><year>1991</year><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">1824863</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name><surname>Kushnir</surname><given-names>I</given-names></name><name><surname>Kolander</surname><given-names>Y</given-names></name><name><surname>Bickels</surname><given-names>J</given-names></name><name><surname>Gortzak</surname><given-names>Y</given-names></name><name><surname>Flusser</surname><given-names>G</given-names></name></person-group><article-title>Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?</article-title><source>Med Oncol</source><volume>31</volume><year>2014</year><fpage>936</fpage><pub-id pub-id-type="pmid">24719037</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name><surname>Assi</surname><given-names>H</given-names></name><name><surname>Missenard</surname><given-names>G</given-names></name><name><surname>Terrier</surname><given-names>P</given-names></name><name><surname>Le Pechoux C</surname><given-names>BonvalotS</given-names></name></person-group><article-title>Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial</article-title><source>Curr. Oncol.</source><volume>17</volume><year>2010</year><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21151406</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name><surname>Provisor</surname><given-names>AJ</given-names></name><name><surname>Ettinger</surname><given-names>LJ</given-names></name><name><surname>Nachman</surname><given-names>JB</given-names></name><name><surname>Krailo</surname><given-names>MD</given-names></name><name><surname>Makley</surname><given-names>JT</given-names></name></person-group><article-title>Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group</article-title><source>J. Clin. Oncol.</source><volume>15</volume><year>1997</year><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8996127</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Hattinger</surname><given-names>CM</given-names></name><name><surname>Pasello</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Picci</surname><given-names>P</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name></person-group><article-title>Emerging drugs for high-grade osteosarcoma</article-title><source>Expert Opin. Emerg. Drugs</source><volume>15</volume><year>2010</year><fpage>615</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">20690888</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><mixed-citation publication-type="other" id="othref0001">K.A. Janeway, H.E. Grier, Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects, Lancet Oncol.. 11(2010) 670&#x02013;678.</mixed-citation></ref></ref-list><sec id="sec0020" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0035a"><supplementary-material content-type="local-data" id="ecom0001"><media xlink:href="mmc1.zip"><alt-text>Image, application 1</alt-text></media></supplementary-material></p></sec><fn-group><fn id="sec0019" fn-type="supplementary-material"><p id="para0007a">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jbo.2018.04.001" id="interref0001">10.1016/j.jbo.2018.04.001</ext-link>.</p></fn></fn-group></back></article>